🇪🇺 Pritor in European Union

EMA authorised Pritor on 11 December 1998

Marketing authorisation

EMA — authorised 11 December 1998

  • Application: EMEA/H/C/000210
  • Marketing authorisation holder: Bayer AG
  • Local brand name: Pritor
  • Indication: Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage.
  • Status: approved

Read official source →

Other Metabolic approved in European Union

Frequently asked questions

Is Pritor approved in European Union?

Yes. EMA authorised it on 11 December 1998.

Who is the marketing authorisation holder for Pritor in European Union?

Bayer AG holds the EU marketing authorisation.